{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:12:29Z","timestamp":1790190749437,"version":"4.1.0"},"reference-count":100,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,9,13]],"date-time":"2018-09-13T00:00:00Z","timestamp":1536796800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.02013","type":"journal-article","created":{"date-parts":[[2018,9,13]],"date-time":"2018-09-13T04:14:24Z","timestamp":1536812064000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":50,"title":["Mesenchymal Stromal Cells Based Therapy in Systemic Sclerosis: Rational and Challenges"],"prefix":"10.3389","volume":"9","author":[{"given":"Juliette","family":"Peltzer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Aletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadira","family":"Frescaline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Busson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Lataillade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Martinaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,9,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1056\/NEJMra0806188","article-title":"Scleroderma","volume":"360","author":"Gabrielli","year":"2009","journal-title":"N Engl J Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nrrheum.2009.238","article-title":"Autoantibodies as predictive tools in systemic sclerosis","volume":"6","author":"Nihtyanova","year":"2010","journal-title":"Nat Rev Rheumatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1097\/01.bor.0000144759.30154.84","article-title":"Illness and art: the legacy of Paul Klee: Curr Opin Rheumatol","volume":"16","author":"Varga","year":"2004"},{"key":"B4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1703327","article-title":"Myeloablative autologous stem-cell transplantation for severe scleroderma","volume":"378","author":"Sullivan","year":"2018","journal-title":"N Engl J Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1002\/art.11073","article-title":"Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population","volume":"48","author":"Mayes","year":"2003","journal-title":"Arthritis Rheum."},{"key":"B6","first-page":"1573","article-title":"Criteria for the classification of early systemic sclerosis","volume":"28","author":"LeRoy","year":"2001","journal-title":"J Rheumatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.mpmed.2009.10.014","article-title":"Systemic sclerosis: clinical features and management","volume":"38","author":"Derrett-Smith","year":"2010","journal-title":"Medicine"},{"key":"B8","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.semarthrit.2014.05.010","article-title":"Mortality and survival in systemic sclerosis: systematic review and meta-analysis","volume":"44","author":"Rubio-Rivas","year":"2014","journal-title":"Semin Arthritis Rheum."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1002\/art.40027","article-title":"Early mortality in a multinational systemic sclerosis inception cohort","volume":"69","author":"Hao","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1136\/ard.2009.114264","article-title":"Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database","volume":"69","author":"Tyndall","year":"2010","journal-title":"Ann Rheum Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"72","author":"van den Hoogen","year":"2013","journal-title":"Ann Rheum Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"15002","DOI":"10.1038\/nrdp.2015.2","article-title":"Systemic sclerosis","volume":"1","author":"Allanore","year":"2015","journal-title":"Nat Rev Dis Primer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/nrrheum.2014.53","article-title":"Fibrosis\u2014a lethal component of systemic sclerosis","volume":"10","author":"Ho","year":"2014","journal-title":"Nat Rev Rheumatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1186\/1755-1536-5-S1-S18","article-title":"Fibrosis in systemic sclerosis: common and unique pathobiology","volume":"5","author":"Bhattacharyya","year":"2012","journal-title":"Fibrogen Tissue Repair"},{"key":"B15","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S0140-6736(11)60982-3","article-title":"Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial","volume":"378","author":"Burt","year":"2011","journal-title":"The Lancet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/S0140-6736(12)62114-X","article-title":"Cardiac involvement and treatment-related mortality after non-myeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: a retrospective analysis","volume":"381","author":"Burt","year":"2013","journal-title":"The Lancet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"311","author":"van Laar","year":"2014","journal-title":"JAMA"},{"key":"B18","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/nrrheum.2017.7","article-title":"Haematopoietic stem cell transplantation for autoimmune diseases","volume":"13","author":"Swart","year":"2017","journal-title":"Nat Rev Rheumatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/nrrheum.2018.34","article-title":"Systemic sclerosis: autologous HSCT is efficacious, but can we make it safer?","volume":"14","author":"Burt","year":"2018","journal-title":"Nat Rev Rheumatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e159","DOI":"10.1016\/j.lpm.2016.05.002","article-title":"Stem cell transplantation and mesenchymal cells to treat autoimmune diseases","volume":"45","author":"Tyndall","year":"2016","journal-title":"Presse M\u00e9d."},{"key":"B21","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1186\/s13075-015-0819-7","article-title":"Update on mesenchymal stem cell-based therapy in lupus and scleroderma","volume":"17","author":"Cras","year":"2015","journal-title":"Arthritis Res Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13287-017-0643-x","article-title":"Safety and effectiveness of stem cell therapies in early-phase clinical trials in stroke: a systematic review and meta-analysis","volume":"8","author":"Nagpal","year":"2017","journal-title":"Stem Cell Res Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e47559","DOI":"10.1371\/journal.pone.0047559","article-title":"Safety of cell therapy with mesenchymal stromal cells (safecell): a systematic review and meta-analysis of clinical trials","volume":"7","author":"Lalu","year":"2012","journal-title":"PLOS ONE"},{"key":"B24","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev-cellbio-100913-013132","article-title":"\u201cMesenchymal\u201d stem cells","volume":"30","author":"Bianco","year":"2014","journal-title":"Annu Rev Cell Dev Biol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/j.1365-2184.1970.tb00347.x","article-title":"The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells","volume":"3","author":"Friedenstein","year":"1970","journal-title":"Cell Prolif."},{"key":"B26","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/00007890-197404000-00001","article-title":"Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo.","volume":"17","author":"Friedenstein","year":"1974","journal-title":"Transplantation"},{"key":"B27","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/jor.1100090504","article-title":"Mesenchymal stem cells","volume":"9","author":"Caplan","year":"1991","journal-title":"J Orthop Res."},{"key":"B28","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1242\/dev.110.4.1001","article-title":"Stem cells: attributes, cycles, spirals, pitfalls and uncertainties Lessons for and from the Crypt","volume":"110","author":"Potten","year":"1990","journal-title":"Development"},{"key":"B29","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/14653240600855905","article-title":"Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement","volume":"8","author":"Dominici","year":"2006","journal-title":"Cytotherapy"},{"key":"B30","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1002\/jcp.21940","article-title":"Regulation of stemness and stem cell niche of mesenchymal stem cells: Implications in tumorigenesis and metastasis","volume":"222","author":"Kuhn","year":"2010","journal-title":"J Cell Physiol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/6529","article-title":"Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta","volume":"5","author":"Horwitz","year":"1999","journal-title":"Nat Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/nm0405-367","article-title":"Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells","volume":"11","author":"Gnecchi","year":"2005","journal-title":"Nat Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1096\/fj.05-5211com","article-title":"Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement","volume":"20","author":"Gnecchi","year":"2006","journal-title":"FASEB J."},{"key":"B34","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1200\/JCO.2000.18.2.307","article-title":"Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy","volume":"18","author":"Ko\u00e7","year":"2000","journal-title":"J Clin Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1046\/j.1365-2141.2002.03767.x","article-title":"Treatment of high-risk acute myelogenous leukaemia by myeloablative chemoradiotherapy followed by co-infusion of T cell-depleted haematopoietic stem cells and culture-expanded marrow mesenchymal stem cells from a related donor with one fully mismatched human leucocyte antigen haplotype","volume":"118","author":"Lee","year":"2002","journal-title":"Br J Haematol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2005.02.001","article-title":"Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients","volume":"11","author":"Lazarus","year":"2005","journal-title":"Biol Blood Marrow Transplant."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/S0140-6736(04)16104-7","article-title":"Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells","volume":"363","author":"Le Blanc","year":"2004","journal-title":"The Lancet"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1002\/sctm.16-0363","article-title":"Mesenchymal stem cell-derived extracellular vesicles as mediators of anti-inflammatory effects: endorsement of macrophage polarization","volume":"6","author":"Lo Sicco","year":"2017","journal-title":"Stem Cells Transl Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1038\/mt.2011.169","article-title":"Gesicles: microvesicle \u201ccookies\u201d for transient information transfer between cells","volume":"19","author":"Breakefield","year":"2011","journal-title":"Mol Ther."},{"key":"B40","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.autrev.2011.04.013","article-title":"B cells in systemic sclerosis: a possible target for therapy","volume":"10","author":"Bosello","year":"2011","journal-title":"Autoimmun Rev."},{"key":"B41","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1080\/03009740802572467","article-title":"Enhanced interleukin-10 production by dendritic cells upon stimulation with Toll-like receptor 4 agonists in systemic sclerosis that is possibly implicated in CCL18 secretion","volume":"38","author":"van Lieshout","year":"2009","journal-title":"Scand J Rheumatol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"e5981","DOI":"10.1371\/journal.pone.0005981","article-title":"Increased frequency and compromised function of T regulatory cells in systemic sclerosis (SSc) is related to a diminished CD69 and TGF\u03b2 expression","volume":"4","author":"Radstake","year":"2009","journal-title":"PLoS ONE"},{"key":"B43","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/bmt.2008.424","article-title":"Allogeneic hematopoietic SCT for patients with autoimmune diseases","volume":"44","author":"Daikeler","year":"2009","journal-title":"Bone Marrow Transplant."},{"key":"B44","doi-asserted-by":"publisher","first-page":"268","DOI":"10.4252\/wjsc.v8.i9.268","article-title":"Immunomodulation by mesenchymal stem cells: Interplay between mesenchymal stem cells and regulatory lymphocytes","volume":"8","author":"Ma","year":"2016","journal-title":"World J Stem Cells"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1089\/scd.2016.0184","article-title":"Effect of mesenchymal stromal cells on T cells in a septic context: immunosuppression or immunostimulation?","volume":"26","author":"Le Burel","year":"2017","journal-title":"Stem Cells Dev."},{"key":"B46","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/cei.12111","article-title":"Mesenchymal stem cells (MSCs) from scleroderma patients (SSc) preserve their immunomodulatory properties although senescent and normally induce T regulatory cells (Tregs) with a functional phenotype: implications for cellular-based therapy","volume":"173","author":"Cipriani","year":"2013","journal-title":"Clin Exp Immunol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.stem.2012.03.007","article-title":"Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-\/FAS-mediated T cell apoptosis","volume":"10","author":"Akiyama","year":"2012","journal-title":"Cell Stem Cell"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1016\/j.jid.2017.02.986","article-title":"Mesenchymal stem cells (MSCs) attenuate cutaneous sclerodermatous graft-versus-host disease (scl-gvhd) through inhibition of immune cell infiltration in a mouse model","volume":"137","author":"Lim","year":"2017","journal-title":"J Invest Dermatol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1136\/ard.2011.150607","article-title":"Bone marrow-derived mesenchymal stem cells from early diffuse systemic sclerosis exhibit a paracrine machinery and stimulate angiogenesis in vitro","volume":"70","author":"Guiducci","year":"2011","journal-title":"Ann Rheum Dis."},{"key":"B50","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00281-015-0505-5","article-title":"Vasculopathy in scleroderma","volume":"37","author":"Asano","year":"2015","journal-title":"Semin Immunopathol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.autrev.2017.05.024","article-title":"The role of endothelial cells in the vasculopathy of systemic sclerosis: a systematic review","volume":"16","author":"Mostmans","year":"2017","journal-title":"Autoimmun Rev."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1002\/art.22698","article-title":"Impairment of endothelial cell differentiation from bone marrow\u2013derived mesenchymal stem cells: New insight into the pathogenesis of systemic sclerosis","volume":"56","author":"Cipriani","year":"2007","journal-title":"Arthritis Rheum."},{"key":"B53","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/scrt119","article-title":"Therapeutic potential for mesenchymal stem cell transplantation in critical limb ischemia","volume":"3","author":"Liew","year":"2012","journal-title":"Stem Cell Res Ther."},{"key":"B54","doi-asserted-by":"publisher","first-page":"163","DOI":"10.15283\/ijsc16053","article-title":"Therapeutic potential of human mesenchymal stem cells for treating ischemic limb diseases","volume":"9","author":"Han","year":"2016","journal-title":"Int J Stem Cells"},{"key":"B55","doi-asserted-by":"publisher","first-page":"e12324","DOI":"10.1111\/micc.12324","article-title":"Mesenchymal stem cells and vascular regeneration","volume":"24","author":"Gu","year":"2017","journal-title":"Microcirculation"},{"key":"B56","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s10456-013-9338-9","article-title":"Scleroderma mesenchymal stem cells display a different phenotype from healthy controls; implications for regenerative medicine","volume":"16","author":"Cipriani","year":"2013","journal-title":"Angiogenesis"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.3899\/jrheum.150996","article-title":"Perivascular cells in diffuse cutaneous systemic sclerosis overexpress activated adam12 and are involved in myofibroblast transdifferentiation and development of fibrosis","volume":"43","author":"Cipriani","year":"2016","journal-title":"J Rheumatol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/j.jid.2017.01.011","article-title":"Bone marrow-derived mesenchymal stem cells expressing thioredoxin 1 attenuate bleomycin-induced skin fibrosis and oxidative stress in scleroderma","volume":"137","author":"Jiang","year":"2017","journal-title":"J Invest Dermatol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/nrrheum.2014.137","article-title":"Transforming growth factor \u03b2\u2013at the centre of systemic sclerosis","volume":"10","author":"Lafyatis","year":"2014","journal-title":"Nat Rev Rheumatol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"e001890","DOI":"10.1136\/bmjopen-2012-001890","article-title":"Expression of transforming growth factor \u03b2 receptor II in mesenchymal stem cells from systemic sclerosis patients","volume":"3","author":"Vanneaux","year":"2013","journal-title":"BMJ Open"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1016\/j.jid.2017.03.032","article-title":"Blockade of PDGF receptors by crenolanib has therapeutic effect in patient fibroblasts and in preclinical models of systemic sclerosis","volume":"137","author":"Makino","year":"2017","journal-title":"J Invest Dermatol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1165\/rcmb.2017-0326OC","article-title":"PD-1\/PD-L1 Pathway mediates the alleviation of pulmonary fibrosis by human mesenchymal stem cells in humanized mice","volume":"58","author":"Ni","year":"2017","journal-title":"Am J Respir Cell Mol Biol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.3727\/096368911X623925","article-title":"Adipose tissue-derived stem cell treatment prevents renal disease progression","volume":"21","author":"Donizetti-Oliveira","year":"2012","journal-title":"Cell Transplant."},{"key":"B64","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/iwj.12034","article-title":"Bone marrow-derived mesenchymal stem cell attenuates skin fibrosis development in mice: a cell-based therapy to alleviating skin fibrosis","volume":"11","author":"Wu","year":"2014","journal-title":"Int Wound J."},{"key":"B65","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jaut.2016.03.013","article-title":"Human adipose mesenchymal stem cells as potent anti-fibrosis therapy for systemic sclerosis","volume":"70","author":"Maria","year":"2016","journal-title":"J Autoimmun."},{"key":"B66","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.apjtm.2016.10.005","article-title":"Adipose tissue-derived stem cells ameliorates dermal fibrosis in a mouse model of scleroderma","volume":"10","author":"Chen","year":"2017","journal-title":"Asian Pac J Trop Med."},{"key":"B67","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1136\/ard.2007.071233","article-title":"Phenotypical and functional characteristics of in vitro expanded bone marrow mesenchymal stem cells from patients with systemic sclerosis","volume":"67","author":"Larghero","year":"2007","journal-title":"Ann Rheum Dis."},{"key":"B68","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13287-016-0444-7","article-title":"Characteristics of human adipose derived stem cells in scleroderma in comparison to sex and age matched normal controls: implications for regenerative medicine","volume":"8","author":"Griffin","year":"2017","journal-title":"Stem Cell Res Ther."},{"key":"B69","doi-asserted-by":"publisher","first-page":"988","DOI":"10.3389\/fimmu.2017.00988","article-title":"Serum-mediated oxidative stress from systemic sclerosis patients affects mesenchymal stem cell function","volume":"8","author":"Fonteneau","year":"2017","journal-title":"Front Immunol."},{"key":"B70","first-page":"183","article-title":"Regulation (EC) No 764\/2008 of the European Parliament and of the Council, In: Core EU Legislation","author":"Smith","year":"2007"},{"key":"B71","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1002\/art.30431","article-title":"Treatment of severe progressive systemic sclerosis with transplantation of mesenchymal stromal cells from allogeneic related donors: report of five cases","volume":"63","author":"Keyszer","year":"2011","journal-title":"Arthritis Rheum."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1038\/sj.leu.2404996","article-title":"Marked improvement of severe progressive systemic sclerosis after transplantation of mesenchymal stem cells from an allogeneic haploidentical-related donor mediated by ligation of CD137L","volume":"22","author":"Christopeit","year":"2008","journal-title":"Leukemia"},{"key":"B73","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s13075-017-1373-2","article-title":"Sustained benefit from combined plasmapheresis and allogeneic mesenchymal stem cells transplantation therapy in systemic sclerosis","volume":"19","author":"Zhang","year":"2017","journal-title":"Arthritis Res Ther."},{"key":"B74","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/jcp.21200","article-title":"Adult mesenchymal stem cells for tissue engineering versus regenerative medicine","volume":"213","author":"Caplan","year":"2007","journal-title":"J Cell Physiol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.trim.2014.03.001","article-title":"Donor age negatively affects the immunoregulatory properties of both adipose and bone marrow derived mesenchymal stem cells","volume":"30","author":"Wu","year":"2014","journal-title":"Transpl Immunol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.bone.2003.07.005","article-title":"Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells","volume":"33","author":"Stenderup","year":"2003","journal-title":"Bone"},{"key":"B77","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.stemcr.2015.01.001","article-title":"In vivo therapeutic potential of mesenchymal stromal cells depends on the source and the isolation procedure","volume":"4","author":"Bortolotti","year":"2015","journal-title":"Stem Cell Rep."},{"key":"B78","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1159\/000110447","article-title":"Direct comparison of human mesenchymal stem cells derived from adipose tissues and bone marrow in mediating neovascularization in response to vascular ischemia","volume":"20","author":"Kim","year":"2007","journal-title":"Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13287-017-0483-8","article-title":"Systematic review of patient factors affecting adipose stem cell viability and function: implications for regenerative therapy","volume":"8","author":"Varghese","year":"2017","journal-title":"Stem Cell Res Ther."},{"key":"B80","doi-asserted-by":"publisher","first-page":"841","DOI":"10.3727\/096368917X694822","article-title":"Phenotypical and functional characteristics of in vitro-expanded adipose-derived mesenchymal stromal cells from patients with systematic sclerosis","volume":"26","author":"Capelli","year":"2017","journal-title":"Cell Transplant."},{"key":"B81","doi-asserted-by":"publisher","first-page":"771","DOI":"10.5966\/sctm.2010-0031","article-title":"Effects of medium supplements on proliferation, differentiation potential, and in vitro expansion of mesenchymal stem cells","volume":"1","author":"Gharibi","year":"2012","journal-title":"Stem Cells Transl Med."},{"key":"B82","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1089\/scd.2016.0349","article-title":"Effect of the microenvironment on mesenchymal stem cell paracrine signaling: opportunities to engineer the therapeutic effect","volume":"26","author":"Kusuma","year":"2017","journal-title":"Stem Cells Dev."},{"key":"B83","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/stem.2298","article-title":"Comprehensive proteomic analysis of mesenchymal stem cell exosomes reveals modulation of angiogenesis via nuclear factor-kappaB signaling","volume":"34","author":"Anderson","year":"2016","journal-title":"Stem Cells"},{"key":"B84","doi-asserted-by":"publisher","first-page":"3608","DOI":"10.1002\/stem.2195","article-title":"Hypoxia differentially modulates the genomic stability of clinical-grade ADSCs and BM-MSCs in long-term culture","volume":"33","author":"Bigot","year":"2015","journal-title":"Stem Cells"},{"key":"B85","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1471-2121-11-11","article-title":"Low physiologic oxygen tensions reduce proliferation and differentiation of human multipotent mesenchymal stromal cells","volume":"11","author":"Holzwarth","year":"2010","journal-title":"BMC Cell Biol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1002\/stem.1191","article-title":"Human mesenchymal stem\/stromal cells cultured as spheroids are self-activated to produce prostaglandin E2 that directs stimulated macrophages into an anti-inflammatory phenotype","volume":"30","author":"Yl\u00f6stalo","year":"2012","journal-title":"Stem Cells"},{"key":"B87","doi-asserted-by":"publisher","first-page":"871","DOI":"10.5966\/sctm.2013-0050","article-title":"Concise review: guidance in developing commercializable autologous\/patient-specific cell therapy manufacturing","volume":"2","author":"Eaker","year":"2013","journal-title":"Stem Cells Transl Med."},{"key":"B88","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.cryobiol.2015.07.003","article-title":"Mesenchymal stromal cells derived from various tissues: biological, clinical and cryopreservation aspects","volume":"71","author":"Marquez-Curtis","year":"2015","journal-title":"Cryobiology"},{"key":"B89","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1002\/stem.1729","article-title":"Do Cryopreserved Mesenchymal Stromal Cells Display Impaired Immunomodulatory and therapeutic properties?","volume":"32","author":"Moll","year":"2014","journal-title":"Stem Cells"},{"key":"B90","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.molmed.2014.06.005","article-title":"MicroRNAs in cancer: biomarkers, functions and therapy","volume":"20","author":"Hayes","year":"2014","journal-title":"Trends Mol Med."},{"key":"B91","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.jcyt.2013.03.005","article-title":"Risk of tumorigenicity in mesenchymal stromal cell-based therapies\u2013bridging scientific observations and regulatory viewpoints","volume":"15","author":"Barkholt","year":"2013","journal-title":"Cytotherapy"},{"key":"B92","doi-asserted-by":"publisher","first-page":"e94","DOI":"10.3324\/haematol.2014.104711","article-title":"Frequent occurrence of non-malignant genetic alterations in clinical grade mesenchymal stromal cells expanded for cell therapy protocols","volume":"99","author":"Capelli","year":"2014","journal-title":"Haematologica"},{"key":"B93","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.jcyt.2015.11.017","article-title":"Chromosomal stability of mesenchymal stromal cells during in vitro culture","volume":"18","author":"Stultz","year":"2016","journal-title":"Cytotherapy"},{"key":"B94","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1182\/blood-2009-05-219907","article-title":"Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation","volume":"115","author":"Tarte","year":"2010","journal-title":"Blood"},{"key":"B95","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.yexcr.2011.12.009","article-title":"Comment to: \u201cSpontaneous transformation of adult mesenchymal stem cells from cynomolgus macaques in vitro\u201d by Z. Ren et al. Exp. Cell Res. 317 (2011) 2950-2957: spontaneous transformation of mesenchymal stem cells in culture: facts or fiction?","volume":"318","author":"Torsvik","year":"2012","journal-title":"Exp Cell Res."},{"key":"B96","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/cpr.12002","article-title":"Stability of human mesenchymal stem cells during in vitro culture: considerations for cell therapy","volume":"46","author":"Binato","year":"2013","journal-title":"Cell Prolif."},{"key":"B97","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.ajhg.2016.02.003","article-title":"Extensive hidden genomic mosaicism revealed in normal tissue","volume":"98","author":"Vattathil","year":"2016","journal-title":"Am J Hum Genet."},{"key":"B98","doi-asserted-by":"crossref","DOI":"10.3824\/stembook.1.97.1","article-title":"From production to patient: challenges and approaches for delivering cell therapies, In: StemBook","author":"Coopman","year":""},{"key":"B99","doi-asserted-by":"publisher","first-page":"628767","DOI":"10.1155\/2015\/628767","article-title":"Adult mesenchymal stem cells: when, where, and how","volume":"2015","author":"Caplan","year":"2015","journal-title":"Stem Cells Int."},{"key":"B100","doi-asserted-by":"publisher","first-page":"4381","DOI":"10.4049\/jimmunol.1401636","article-title":"Differential efficacy of human mesenchymal stem cells based on source of origin","volume":"193","author":"Collins","year":"2014","journal-title":"J Immunol."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02013\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T06:43:26Z","timestamp":1662014606000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02013\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,13]]},"references-count":100,"alternative-id":["10.3389\/fimmu.2018.02013"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.02013","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,13]]},"article-number":"2013"}}